Maier, Rolf F.
Hummler, Helmut
Kellner, Ulrich
Krohne, Tim U.
Lawrenz, Burkhard
Lorenz, Birgit
Mitschdörfer, Barbara
Roll, Claudia
Stahl, Andreas
Article History
Accepted: 25 March 2022
First Online: 4 May 2022
Declarations
:
: Potential author conflicts of interest are summarized in table form on a separate form (2010 AWMF form). The disclosed potential conflicts of interest were assessed by the lead guideline coordinator, the members of the author group, and the guideline officer of the GNPI. Some authors have relationships to the pharmaceutical companies that produce drugs for the treatment of retinopathy of prematurity. However, since this guideline relates explicitly to the diagnosis and not to the treatment of retinopathy of prematurity, no relevant conflicts of interest in the sense of personal advantages that could have compromised the authors’ impartiality have been expressed. The overview in table form can be viewed on the AWMF homepage: ExternalRef removed
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case. The supplement containing this article is not sponsored by industry.